Sandoz Inc. issued the following announcement on July 1.
Sandoz Inc. (Sandoz), a Novartis Division, today announced an exclusive agreement with Adamis Pharmaceuticals Corporation (Adamis) whereby Sandoz will distribute and commercialize SYMJEPI™ (epinephrine) 0.3 mg Injection in the United States. The agreement also covers SYMJEPI.15 mg Injection, which is pending review by the U.S. Food and Drug Administration.
SYMJEPI 0.3 mg Injection is indicated for the emergency treatment of allergic reactions (Type 1) including anaphylaxis to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis. SYMJEPI 0.3 mg is intended for immediate administration in patients who weigh approximately 66 pounds or more and who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.
“SYMJEPI is an affordable alternative treatment for patients who are at increased risk for anaphylaxis,” said Carol Lynch, President of Sandoz Inc. “As one of the largest pharmaceutical companies in the US, Sandoz has the right capabilities to support broad patient access to SYMJEPI and we are pleased that Adamis chose us to commercialize this important product. We look forward to making this important medicine available to patients.”
Original source can be found here.